Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: bruker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $72.00 | Buy | Guggenheim |
| 12/10/2024 | $66.00 | Neutral | UBS |
| 12/5/2024 | $60.00 | Sell → Neutral | Goldman |
| 10/15/2024 | $75.00 | Overweight | Barclays |
| 9/30/2024 | Outperform → Peer Perform | Wolfe Research | |
| 8/28/2024 | $78.00 | Overweight | Wells Fargo |
| 6/3/2024 | $85.00 | Buy | Jefferies |
| 2/14/2024 | $60.00 → $90.00 | Neutral → Overweight | JP Morgan |
| 12/19/2023 | $72.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | $80.00 | Outperform | Wolfe Research |
Groundbreaking LUMOS II ILIM QCL-based IR microscope sets new standards in speed and resolution Bruker Corporation (NASDAQ:BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108014369/en/LUMOS™ II ILIM quantum cascade laser (QCL) based infrared imaging microscope for pharma and life science research (Photo: Business Wire) The LU
Bruker Corporation (NASDAQ:BRKR) announced today it will participate in the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 13th, 2025 at 3:45 PM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the e
Bruker Corporation (NASDAQ:BRKR) today commented on the ruling of the U.S. District Court for the District of Delaware in the case involving GeoMx® Digital Spatial Profiler products sold by its NanoString business. Yesterday, the Court issued its ruling on the post-trial motions that followed the November 2023 jury verdict in the patent infringement case between NanoString and 10x Genomics. In its ruling, the District Court upheld the jury's damages award of approximately $31.6 million (plus interest and a damages true-up for GeoMx sales since the November 2023 verdict), while declining 10x's request for enhanced damages and attorneys' fees. The Court stated that it would grant 10x's reques
PLEASANTON, Calif., Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (NASDAQ:BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023. The injunction, which the Court said it wi
State-of-the-art instrument enhances research in structural biology and protein analysis Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis. The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biolo
Upgradable Large-Sample System Sets New Performance Standard for Cost-Effective AFMs At the 2024 MRS Fall Meeting & Exhibit, Bruker Corporation (NASDAQ:BRKR) today announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest addition to the industry-leading Dimension® AFM product line, which has had more than 4600 systems installed around the world. With the latest-generation NanoScope® 6 controller, this new small-footprint AFM delivers wider access to Bruker's exclusive PeakForce Tapping® technology and over 50 AFM modes. The upgradability and enhanced ease of use of Dimension Nexus provides an optimal intersection of performance and value fo
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Bruker Corporation (NASDAQ:BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time Nasdaq 51st Investor Conference in London, UK Tuesday, December 10, 2024, at 6:30 a.m. Eastern Time Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in
This strategic partnership leverages the complementary strengths of Dragonfly Energy and Bruker, bringing Dragonfly Energy's thorough expertise in liquid and solid-state battery technology together with Bruker's comprehensive suite of analytical solutions for battery research, development and manufacturingThe collaboration provides a path toward improving Dragonfly Energy's current and next-generation battery technologies and analytical testing methods using Bruker equipment and analytical expert knowledgeBruker's involvement greatly enhances Dragonfly Energy's in-depth scientific understanding of batteries and battery materials through advanced analytical methods based on magnetic resonance
New Technology Expands Antibody Compatibility and Doubles Throughput while maintaining Tissue Integrity and Lack of Cross-Reactivity Bruker Corporation (NASDAQ:BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). Launched in 2022, the CellScape platform has advanced the field of spatial proteomics with differentiated quantitative performance enabled by a unique combination of best-in-class resolution and high dynamic range (HDR) imaging. CellScape captures the entire continuum of protein expression in a biological sample—from least to most abundant—while capturing fine morphological de
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-
Combining Dynamic Biosensors' Innovative Technologies with Bruker's High-Performance SPR Portfolio to Establish a Leading Biosensors Business Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, an
Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: "Our teams delivered excellent revenue growth in the second quarter and a solid first half of 2024, despite soft general market condi
Bruker Corporation (NASDAQ:BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q2 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 17, 2024 to stockholders of record as of June 3, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsco
Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 Updated FY 2024 guidance: Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13% yoy. Organic revenue growth maintained at 5% to 7% yoy CER revenue growth of 12% to 14% yoy, including closed Chemspeed and ELITech acquisitions, up from prior guidance of 8% to 10% yoy Non-GAAP EPS of $2.79 to $2.84, up $0.08 from prior guidance, including ELITech EPS accretion, but excluding still pending EPS-dilutive NanoString acquisition
Bruker Corporation (NASDAQ:BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-41
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling i
3 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
10-Q - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K/A - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
424B5 - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00
UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00
Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00
Barclays initiated coverage of Bruker with a rating of Overweight and set a new price target of $75.00
Wolfe Research downgraded Bruker from Outperform to Peer Perform
Wells Fargo initiated coverage of Bruker with a rating of Overweight and set a new price target of $78.00
Jefferies resumed coverage of Bruker with a rating of Buy and set a new price target of $85.00
JP Morgan upgraded Bruker from Neutral to Overweight and set a new price target of $90.00 from $60.00 previously
Wells Fargo initiated coverage of Bruker with a rating of Equal Weight and set a new price target of $72.00
Wolfe Research initiated coverage of Bruker with a rating of Outperform and set a new price target of $80.00
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab
Bruker (NASDAQ:BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker's biopharma PAT portfolio with its well-established products. Financial details were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104658012/en/Tornado's proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Busines
High-end STEM Technology Expands Bruker's Portfolio for Materials Science Research Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker's product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005639/en/Dr. Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ (Photo: Business Wire) Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief Business